Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BrukerFRA:BKD -1.17%86 EV-to-EBIT is 69.87 as of Aug. 19, 2026, which is 182% above its 10-year median of 24.75. GuruFocus rates FRA:BKD with a GF Score™ of 86/100 and a GF Value™ of €52.58 (Fairly Valued). The stock has 11 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Bruker ranks worse than 90.68% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bruker's Enterprise Value is €8,894 Mil.
Bruker's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €127 Mil. Therefore, Bruker's EV-to-EBIT for today is 69.87.
The historical rank and industry rank for Bruker's EV-to-EBIT or its related term are showing as below:
FRA:BKD'
s EV-to-EBIT Range Over the Past 10 Years
Min: 16.89 Med: 24.75 Max: 137.09
Current: 70.03
During the past 13 years, the highest EV-to-EBIT of Bruker was 137.09. The lowest was 16.89. And the median was 24.75.
FRA:BKD's EV-to-EBIT is ranked worse than 90.68% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.185
vs FRA:BKD: 70.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bruker's Enterprise Value for the quarter that ended in Jun. 2026 was €9,416 Mil.
Bruker's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bruker EV-to-EBIT Related Terms
Bruker EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bruker's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bruker's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bruker EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bruker's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bruker's EV-to-EBIT falls into.
Bruker's current Enterprise Value is €8,894 Mil.
Bruker's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bruker (FRA:BKD) has a EV-to-EBIT of 69.87 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bruker and its competitors. This is 182% above median its historical median of 24.75. Over the past decade, Bruker's EV-to-EBIT has ranged from 16.89 to 137.09. According to the industry distribution chart, Bruker ranks #428 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 90.7%.
Is Bruker's EV-to-EBIT too high?
Bruker's current EV-to-EBIT of 69.87 is 182% above median its 10-year median of 24.75. Over the past 10 years, this metric has ranged from a low of 16.89 to a high of 137.09. The Medical Devices & Instruments industry median EV-to-EBIT is 19.19. Bruker's value of 69.87 is 264.2% above this industry median. Based on the distribution chart, Bruker ranks #428 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bruker has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bruker's EV-to-EBIT compare to GKOS and BIO?
According to the Medical Devices & Instruments industry distribution chart, Bruker ranks #428 out of 472 companies for EV-to-EBIT. This places Bruker in the lower half of its industry. The industry median EV-to-EBIT is 19.19. Bruker's value of 69.87 is 264.2% above this benchmark. Historically, Bruker's own EV-to-EBIT has ranged from 16.89 to 137.09 over the past decade. While the company's 10-year median is 24.75 vs. the industry median of 19.19, Bruker has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.19, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bruker's current EV-to-EBIT of 69.87 is 264.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bruker and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bruker's current EV-to-EBIT is 69.87, which is 182% above median its own 10-year median of 24.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bruker stock overvalued right now?
Based on GuruFocus' analysis, Bruker (FRA:BKD) is currently considered Fairly Valued. The stock's GF Value™ is €52.58, compared to a current price of €49.03 — trading 6.8% below its estimated fair value. The current EV-to-EBIT is 69.87, which is 182% above median its 10-year median of 24.75 and 264.2% above the Medical Devices & Instruments industry median of 19.19. Bruker's overall GF Score™ is 86/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bruker (FRA:BKD), the current EV-to-EBIT is 69.87 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bruker (FRA:BKD) Overvalued in 2026?
Based on GuruFocus' analysis, Bruker stock appears to be undervalued.
The current stock price of €49.03 is trading 6.8% below its estimated GF Value™ of €52.58.
GuruFocus considers Bruker to be Fairly Valued.
Key valuation signals for FRA:BKD:
EV-to-EBIT: 69.87 (182% above median its 10-year median of 24.75)
GF Value™: €52.58 vs. price of €49.03 (6.8% below fair value)
Industry Position: 264.2% above the Medical Devices & Instruments median (#428 of 472)
No single metric tells the full story. See the FRA:BKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
86GF Score
Get the complete analysis for FRA:BKD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BKD has been successfully added to your 
